Specific therapeutic activity of chemical compounds or medicinal preparations (A61P)

Composition for treating lung cancer, first non-small cells lung cancer (nsclc)

Invention refers to biotechnology and medicine. What is described is an active immunostimulating vaccine containing at least one RNA, preferentially iRNA coding at least two antigens evoking the immune response in a mammal and used for treating lung cancer, first non-small cells lung cancer (NSCLC), preferentially specified among three primary subtypes, squamous cell carcinoma, adenocarcinoma and large-cell lung carcinoma, or NSCLS-related disorders.

Method of evaluation of antivariolic activity of therapeutic and prophylactic preparations

Method of evaluation of antivariolic activity of therapeutic and prophylactic preparations comprises administering to the body of the animal model of control and test groups in a predetermined scheme of suspension of investigational antiviral preparation. Their intranasal infection is carried out with the strain of monkeypox virus, followed by incubation of the virus in animal bodies. The concentration of virus in the lungs of animals is determined, followed by the calculation of estimated indicators. The animal model is used as ordinary steppe heterosexual marmots Marmota bobak of 1-2-year-old age. The strain of monkeypox virus the strain of monkeypox virus V79-1-005 is used, deposited in the State collection of causative agents of viral infections and rickettsial diseases of the Federal budget institution of science State Research Centre of Virology and Biotechnology "Vector" under the registration number V-309.

Medication for stimulation of cardiac muscle vascularisation in its postinfarction remodelling in experiment

As a medication, providing the said stimulation, the application of streptozotocin is suggested in experiment on rats. The preparation is introduced single time intraperitoneally in a dose of 60 mg/kg two weeks after performing coronaroocclusion to the animals.

Diaminoheterocyclic carboxamide compound

Compounds can find application for preventing or treating cancer, lung cancer, non-small cells lung cancer, small-cell lung cancer, EML4-ALK hybrid polynucleotide-positive cancer, EML4-ALK hybrid polynucleotide-positive lung cancer or EML4-ALK hybrid polynucleotide-positive non-small cells lung cancer. In formula (I) -X-: group of formula , A represents chlorine, ethyl or isopropyl; R1 represents phenyl wherein carbon in the 4th position is substituted by the group -W-Y-Z, and carbon in the 3rd position can be substituted by a group specified in a group consisting of halogen, R00 and -O-R00; R00: lower alkyl which can be substituted by one or more halogen atoms; -W-: a bond, piperidine-1,4-diyl or piperazine-1,4-diyl; -Y- represents a bond; Z represents a monovalent 3-10-membered monocyclic non-aromatic heterocyclic ring which contains 1 to 4 heteroatoms specified in a group consisting of nitrogen, oxygen and sulphur, which can be substituted by one or more substitutes R00; R2 represents (i) an optionally bridged saturated C3-10cycloalkyl which can be substituted by one or more groups specified in -N(lower alkyl)2, lower alkyl, -COO-lower alkyl, -OH, -COOH, -CONH-RZB and morpholinyl, or (ii) a monovalent 3-10-membered monocyclic non-aromatic heterocyclic ring which contains 1 to 4 heteroatoms specified in a group consisting of nitrogen, oxygen and sulphur, which can be substituted by one or more groups specified in a group consisting of lower alkyl, -CO-lower alkyl, oxo, -CO-RZB and benzene; and RZB: phenyl which can be substituted by a group consisting of halogen and -O-lower alkyl; R3 represents -H.

Substituted cyclohexyldiamines

Invention relates to a compound of general formula (1), in which Y1, Y1', Y2, Y2', Y3, Y3', Y4 and Y4' denote -H; R1 and R2 denote an unsubstituted -C1-8-aliphatic; R3 denotes an unsubstituted -C6-16-aryl; R4 denotes -H or -C(=O)R0, where R0 denotes -C1-8-aliphatic, unsubstituted or mono- or polysubstituted with substitutes independently selected from a group consisting of -F, -Cl, -Br, -I and -CN; Q denotes unsubstituted -C1-8-aliphatic-heteroaryl; X denotes =O, =CR6R7 or =N-R6, wherein R5 denotes -NH2, -NH-(unsubstituted-C1-8-aliphatic) or -N-(unsubstituted-C1-8-aliphatic)2, if X denotes =O, or R5 and R6 together form a 5-member ring in which the remaining ring atoms independently denote C, N, S or O, wherein the 5-member ring denotes 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, oxazolyl or thiazolyl, in each case unsubstituted or monosubstituted with unsubstituted C1-C8aliphatic or =O, or unsubstituted tetrazolyl, if X denotes =N-R6, or R5 and R6 together form unsubstituted phenyl, and R7 denotes -H, if X denotes =CR6R7, where "aliphatic" in each case represents a branched or straight, saturated hydrocarbon residue; "aryl" in each case independently denotes a carboxylic ring system containing at least one aromatic ring which does not contain heteroatoms, where the aryl may be optionally condensed with other saturated, (partially) unsaturated or aromatic ring systems; "heteroaryl" denotes indolyl; in the form of a separate stereoisomer or a mixture thereof, in the form of free compounds and/or physiologically compatible salts thereof. The compound of formula

Method of surgical treatment of acute pancreatitis with early enteral intraoperative nutrition of patient

In the process of preoperative preparation imunofan is introduced to a patient intramuscularly in a dose of 1 ml one time per day. After that, laparoscopy with revision of the abdominal cavity organs, opening of the omental bursa and its washing with solutions of antiseptics, and formation of the external cholecystoma are performed. Intraoperatively at the stage of the omental bursa drainage and before performing cholecyctomy, into the stomach introduced is a thin probe for enteral nutrition, through which early intraoperative nutrition is realised by introduction of liquid food "Diason" at a rate of 30 ml/hour in an amount of 450-500 ml on the first day of the postoperative period. In the postoperative period introduction of imunofan in the same dose is continued for 9 days. Introduction of "Diason" food through the thin probe is also continued on the second day of the postoperative period at a rate of 30 ml/hour in an amount of 450-500 ml, on the third day at a rate of 45-60 ml/hour in an amount of 700-750 ml, on 4 and 5 day at a rate of 80-90 ml/hour in an amount of 950-1000 ml, from 6 to 9 days at a rate of 125-150 ml/hour in an amount of 1500-2000 ml. On the 10-th day after operation the probe of enteral nutrition is removed. After that, a seeping type of nutrition is realised, in the process of which a drink supportan or nutridrink is introduced to the patient in an amount of 200 ml 3-4 times per day until complete recovery of the trophological status.

Method of production of anti-luteolytic blood - alb, method of treatment and prevention of postpartum obstetric and gynecological diseases in cows

Method for production of anti-luteolytic blood - AlB is that luteolisate is administered subcutaneously to gelding twice with an interval of 14 days at a dose of 20 ml each, containing parts of the corpus luteum of pregnancy of cows, and after 14 days after the second administration the blood is taken from the jugular vein. The method of treatment and prevention of persistent corpus luteum, subinvolution of uterus and postpartum endometritis in cows comprises at the background of general therapy the use of anti-luteolytic blood that is administered subcutaneously in the neck region twice at a dose of 10 ml each with an interval of 6 days.

Method of treating arthritis

Invention refers to medicine, namely to therapy, and can be used for treating arthritis in a mammal, involving administering N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulphanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulphonyl)benzene sulphonamide (ABT 263).

Adhesive plaster containing bisoprolol

Invention refers to medicine. What is described is an adhesive plaster, wherein each of the elements of a carrier, a protective film and an adhesive layer has a flat rectangular shape, while a projecting portion is formed on a surface from the carrier of the adhesive plaster angularly. Besides, the adhesive plaster can be formed to have a middle portion and a periphery, while the projecting portion can be formed angularly after the rectangular middle portion. Besides, between adjoining, at least two projecting portions there can be presented a connective component element wherein the thickness of the adhesive plaster is lesser than that of the adhesive plaster in the projecting portion.

Medical glue

Medical glue "Neosulphacrylate" contains, wt.p.: ethyl-α-cyanacrylate 76.5-85.0, 3-methacrylcarboxysulpholane 9.0-12.5, decylmetacrylate 6.0-11.0.

Method of increasing oxygen tension in blood of patients with chronic heart failure

To increase oxygen tension in blood of a patient with the chronic heart failure, antioxidant medication of ethylmethylhydroxypyridine malate in an amount of 50-200 mg is introduced to the patient one time.

Method of obtaining complex antibacterial immunomodulating preparation

Invention relates to the chemical-pharmaceutical industry and represents a method of obtaining a complex preparation for the application in veterinary, possessing immunomodulating and antiseptic properties, which includes mixing succinic acid, levamisole and formalin in distilled water with the following component ratio, wt %: levamisole - 3.0%-3.5%; succinic acid - 2.0%-2.5%; formalin - 0.3%-0.5%, distilled water - the remaining part; sterilisation of the solution by autoclaving is performed in a mode of 1 atm for 20 minutes.

Medication for reduction of hepatitis c virus reproduction

Invention represents a medication for reduction of the hepatitis C virus reproduction, which contains at least one polyprenyl phosphate or polyprenyl pyrophosphate with a number of isoprene units from 9 to 20, mainly from 13 to 18, either a mixture of different polyprenyl phosphates or different polyprenyl pyrophosphates, or a mixture of different polyprenyl phosphates and polyprenyl pyrophosphates with a specified number of isoprene units in a weight ratio from 5:1 to 20:1.

Therapeutic agent for preventing and treating chronic liver diseases

Invention refers to a therapeutic agent for preventing and treating chronic liver diseases. The above agent represents amaranth oil prepared by cold pressing of amaranth seed kernels and coats, to be used in a dose of 62.5 - 250 mg/kg of body weight.

Systemic treatment of blood-sucking parasites and blood consuming parasites by oral administration of antiparasitic

Declared group of inventions refers to veterinary science and aims at controlling blood-sucking parasites and consuming parasites. The composition contains an antiparasitic effective subtoxic amount of imidacloprid in a single dose making 0.25 mg/kg to 30 mg/kg for oral delivery. Imidacloprid is the only antiparasitic being an ingredient of the composition. What is declared is using the above composition. The subtoxic amount of imidacloprid in a single dose makes 0.25 mg/kg to 30 mg/kg. The infestation is eliminated within 1-72 hours after administration of the single dose.

Method of treatment coccidiosis of poultry

Active agent the amides 1 of lauric acid (n=10), amides 1 of myristic acid (n=12), lauric acid (n=10) and myristic acid (n=12) of acids are applied, which are used in the form of salts with pharmacologically acceptable acids.

Stabilised composition for treating psoriasis

Invention refers to medicine and describes a non-aqueous ointment containing a compound of vitamin D, corticosteroid and ester of N,N-di(C1-C8)alkylamino-substituted (C4-C18)alkyl(C2-C18)carboxylic acid in Vaseline, optionally containing mineral oil and tocopherol.

Combination preparations with cytokine antagonist and corticosteroid

Group of inventions refers to treating arthropathies, such as arthrosis and inflammatory loss of cartilage, tendon disorders and/or degenerative spine diseases. What is presented is a pharmaceutical composition for the above application, containing a corticosteroid and a cytokine antagonist - a natural or recombinant protein of interleukin IL-1Ra antagonist, particularly orthokine or anakinra, and optionally a growth factor; the composition is injectable into an injured nerve root, or into an injured intervertebral disk, or into their local context, or for intraarticular injection. There are presented: a kit comprising the pharmaceutical composition with the above cytokine antagonist and optionally the growth factor, and the pharmaceutical composition with the corticosteroid; using the above cytokine antagonist and optionally the growth factor for preparing the pharmaceutical composition to be used in combination therapy together with the corticosteroid for the above application; using the corticosteroid for preparing the pharmaceutical composition to be used in combination therapy with the above cytokine antagonist and optionally the growth factor for treating the above arthropathies, tendon disorders and/or degenerative spine diseases.

Biomaterial and preparation with biomaterial, stimulating anti-tumour activity

Described is biomaterial, stimulating the anti-tumour activity, which contains lyophilisate of postnatal induced lymphatic nodes (PNILN) of a patient with cancer. Described is a preparation, stimulating the anti-tumour activity, which contains as an active substance lyophilisate of PNILN of the patient with cancer, and as a solvent, water for injections, cremofor RH-40, an emulsifier T-2, peach oil, glycerol, Kollidon CL-M and benzyl alcohol with the specified component ratio.

Cd37-immunotherapeutic combination therapy and using it

Group of inventions refers to methods for reducing B-cell count or treating a disease or disorder related to pathological activity of B-cells. That is ensured by administering a therapeutically effective amount of CD37-specific binding molecule and a therapeutically effective amount of mTOR or PI3K inhibitor into an individual. There are also presented a composition and a kit for treating non-Hodgkin lymphoma.

Method of treating alzheimer's disease

Group of inventions refers to medicine and concerns using a peptide conjugated with a protein representing a keyhole limpet hemocyanin (KLH) protein used as an immunogen for preparing antibodies specifically recognising any of prevailing versions of beta-amyloid peptide Aβ40 and Aβ42; or using an antibody, or an active fragment, or an antibody derivative of the above peptide in preparing a therapeutic agent for preventing and/or treating a disease characterised by amyloid accumulation in the patient's brain.

Method for increase of pharmacological activity of active agent of drug preparation and pharmaceutical composition

Present group of inventions refers to medicine, namely to therapy and pharmacology, and can be used to increase pharmacological activity and therapeutic efficacy of drug preparations of activated-potentiated forms of hyperdiluted antibodies. That is ensured by administering a pharmaceutical composition containing activated potentiated pathogenic antigen and endothelial NO-synthase antibodies.

Ointment for burns, folliculitis, furunculosis, vasculitis treatment and wound healing

Invention refers to the pharmaceutical industry, namely to an ointment for burns, folliculitis, furunculosis, vasculitis treatment and wound healing. The ointment for burns, folliculitis, furunculosis, vasculitis treatment and wound healing containing: bees wax, line seed oil, kerosene and visceral fat of pig taken in certain proportions.

Method for correction of endothelial dysfunction by solution of homoeopathic dilutions of vascular endothelial growth factor antibodies

Invention refers to medicine, namely to experimental cardiology and pharmacology, and concerns correction of endothelial dysfunction. That is ensured by administering a mixture of solutions of homoeopathic dilutions of monoclonal antibodies to vascular endothelium growth factor (VEGF) intragastrically into Wistar white male rats 2 times a day in a dose of 4.5 mg/kg for 28 days with underlying intraperitoneal administration of L-NAME in a dose of 12.5 mg/kg a day.

Method for correction of endothelial dysfunction by solution of homoeopathic dilutions of interleukin-1 antibodies

Invention refers to medicine, namely to experimental cardiology and pharmacology, and concerns correction of endothelial dysfunction. That is ensured by administering a mixture of solutions of homoeopathic dilutions of monoclonal antibodies to interleukin-1 intragastrically into Wistar white male rats 2 times a day in a dose of 4.5 mg/kg for 28 days with underlying intraperitoneal administration of L-NAME in a dose of 12.5 mg/kg a day.

Method for correction of endothelial dysfunction

Invention refers to medicine, namely to cardiology and pharmacology, and concerns correction of endothelial dysfunction. That is ensured by administering an activated potentiated form of vascular endothelial growth factor (VEGF) antibodies in an effective amount.

Method for preventing and treating bronchial asthma, complicating respiratory viral infections and other respiratory inflammatory diseases

Invention refers to medicine, namely to therapy and infectious diseases, and can be used for preventing and treating bronchial asthma, complicating respiratory viral infections and other respiratory inflammatory diseases. That is ensured by a combined inhibition of p-gene of the respiratory syncytial virus (further - RSV) and anti-inflammatory murine il-5 gene; p-gene of the RSV required for the cell replication is inhibited using a created molecule of small interfering RNA (siRNA) - SEQ ID NO 1 (siP1), while anti-inflammatory murine il-5 gene is inhibited using a created molecule of siRNA - SEQ ID NO 15 (siIL4-408). They are used to develop preparations containing therapeutically effective amounts thereof to be used intranasally.

Topical herbal formulation for treating acne and skin disorders

Invention refers to an herbal formulation of topical nanoemulsion for treating acne-related skin disorders. The above formulation contains an aqueous phase comprising a therapeutic agent, rose water and/or lemon juice, and an oil phase containing an essential oil, a non-ionic surfactant and an accessory surfactant. The aqueous and oil phases are related within the range of 1:1 to 1:2, while a particle size of the herbal formulation is less than 5 nm. The essential oil is presented by tea tree oil, basil oil, rosemary oil, lavender oil, jojoba oil, bergamot oil, clove oil and peppermint oil. The invention also refers to a method for preparing the herbal formulation which involves providing the aqueous and oil phases, mixing the above phases to produce a mixture to be emulsified with the non-ionic surfactant to prepare a macroemulsion. The prepared macroemulsion is mixed with ethanol to produce a nanoemulsion with a particle size less than 5 nm.

Method for optimising mental activity of trainees

Invention refers to medicine, namely to neurology and concerns improving t mental activity of trainees. That is ensured by daily administration of caffeine 0.2 g followed by self-massage of the head and neck. Self-massage involves performing stroking, compression and rubbing spiral motions started from the head periphery from the back to front scalp border. That is followed by self-massage of the cervical region started with stroking motions from the shoulder joint to the scalp, then pressing up motions in the same direction and rubbing motions circularly with four fingers from the shoulder joint to the occipital bone. Self-massage of the head and neck finally involves stroking motions.

Method of treating patients with pulmonary tuberculosis with accompanying non-specific bronchites

For treatment of patients with pulmonary tuberculosis with accompanying non-specific bronchitis at the background of carrying out standard anti-tuberculosis therapy from the first day of treatment additionally daily for 3 months the preparation Wobenzym is introduced in a dose of 1 tablet 2 times per day, 30 minutes before meal, and inhalation with a solution of the preparation Hixozide in a dose of 350 mg in 10 ml of water for injections is performed 2 times per week, the course constitutes 24 procedures.

Coronarodilating medication

Invention represents a coronarodilating medication in the form of a tablet, which contains a solution of levomenthol in menthyl isovalerate (validol), isomalt, and calcium or magnesium stearate.

Method of correcting haemostatic disorders in case of chronic calculous cholecystitis at background of chronic hepatitis or cirrhosis of liver

To correct haemostatic disorders in case of chronic calculous cholecystitis at the background of chronic hepatitis or cirrhosis of liver, preoperative correction of haemostasis with the preparation prothromplex 600, introduced intravenously at a rate not higher than 2 ml/min in a dose of 20 IU/kg of the patient's body weight, is carried out 3 days before endosurgical treatment. After that, on the first day after operation 20 IU/kg of prothromplex 600 and additionally 10 mg/kg of etamsylate and 25 mg/kg of aminomethyl are introduced intravenously. The preparations are introduced 1 time per day for 3 days with obligatory control of haemostasis indices.

Irinotecan liposomes or its salts, method for preparing them

Invention refers to pharmaceutics and concerns irinotecan liposomes or its hydrochloride containing irinotecan or its hydrochloride, neutral phospholipid and cholesterol, wherein the weight ratio of cholesterol to neutral phospholipid makes 1:3-5, and a method for preparing them.

Therapeutic agents 713

Invention refers to compounds of formula

Tosylate salt of 5-pyrazolyl-2-pyridone derivative effective in copd treatment

Invention refers to a compound representing 4-methylbenzene sulphonate 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulphonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide, and to its new crystalline form. The invention also refers to a method for preparing the above compound and to a pharmaceutical composition, for treating a disease or a condition wherein inhibition of neutrophilic elastase activity with the above compound and/or crystalline form is considered to be effective.

Antibacterial compounds

Invention refers to a pharmaceutical composition of 2,2′-di(pyridin-4-yl)-1H,1′H-5,5′-bibenzo[d]imidazole, as well as to using it in producing a drug for treating C. Difficile-associated diarrhoea (CDAD) by selective bacteriostatic and/or bactericidal activity on Clostridium difficile as compared to C. perfringens, Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, Bacillus subtilis and Bacteroides fragilis.

New peptide and its application

Invention relates to a peptide represented by the formula (I) X1-Leu-X2-Leu-X3, where X1 is Glu or Asp, X2 is His, Lys or Arg, X3 is Asp or Glu, at that Glu, Asp, Leu, His, Lys and Arg, or its pharmaceutically acceptable salt and its compositions for treatment or prevention of cartilage damage and/or arthritis.

Fungicidal preparation

Preparation can be applied for elimination of fungi and in treatment of diseases, caused by fungi, as well as for the prevention of damage by fungi to different materials and agricultural products. The fungicidal preparation represents an associate of 5-[3,5-dichloro-2-hydroxybenzylidine)amino]-4-hydroxy-1H-pyrimidine-2-one with 1,2,3,4,5-pentahydroxy-6-methylaminohexane and corresponds to the following formula: . Compounds were obtained in the crystalline form, and their structure is proved by spectra of proton magnetic resonance in dimethylsulphoxide.

Method of endovascular prevention of endotoxinemia in laparoscopic interventions in patients with acute abdominal pathology, complicated with peritonitis

At the first stage a puncture of the right femoral artery or the right radial artery by Seldinger is performed with further successive catheterisation of the mouth of superior and inferior mesenteric arteries. After that, infusion of 0.5 ml of a 15% solution of xantinol nicotinate and 1.0 ml of a 2% lidocaine solution, diluted in 20.0 ml of a 0.9% solution of sodium chloride is performed. Introduction is carried out under X-ray control.

Method of treating periodontal diseases

As a medication, arresting inflammatory phenomena immobilised tin fluoride is used. The medication represents a composition, prepared from 3 g of a polysorb powder and 100 ml of a 0.63% solution of tin fluoride. The composition is introduced in the form of applications or on turundas, providing action of the solution for 20 minutes.

Method for modulation of biological functions associated with ageing process of senior or senile pet partners

Present invention refers to a method for modulation of biological functions associated with the ageing process in a senior or senile pet partner specified in a small/medium dog, big dog and a cat, involving feeding a pet partner with an effective amount of a composition containing at least one omega-3 polyunsaturated fatty acid and various combinations of amino acids, minerals and antioxidants in amounts effective for an increase of activity, vitality, protection of cartilages, muscle mass maintenance, better digestion and quality of skin and hair at a dry basis. Besides, feeding the animal with the following composition enables inducing favourable changes of gene expression in the animal associated with several biological cascades corresponding to higher quality of life in the above animal.

Method of complex treatment of arterial hypertension in case of metabolic disorders

Method includes carrying out drug treatment, diet therapy, physical exercise, balneotherapy. Drug treatment includes intake of an ACE inhibitor or a beta-blocker 30-40 minutes before the first breakfast. 2-2.5 hours after supper methmorphine in a dose of 500-1000 mg/day is taken in. Diet therapy includes fractional feeding with the calorie content of 1200 kilocalories from Monday to Friday. On Saturday the calorie content is reduced to 800-900 kilocalories, and on Sunday - to 600-700 kilocalories. The physical exercise is carried out in the form of walking in a slow tempo, with stops, with the total duration of 90-120 minutes. Balneotherapy is started with carrying out in the morning of a rain fresh water shower. Then, manual superficial massage of the neck zone is carried out. Baths take place in the period from 12 to 17 o'clock. For their carrying out hydrocarbonate-sulfate-sodium mineral water from Belokurikha resort with an increased content of silicic acid and fluorine, and mineralisation of 0.4 g/l is applied. Radon concentration for bath realisation constitutes 3.9-4.6 nCi/dm3, water temperature is 36-37°C. The duration of the bath time is five minutes on the first day, on the second day - eight minutes, on the third day - ten minutes, on the fourth day - rest, on the fifth and sixth days - twelve minutes, on the seventh day - fifteen minutes, on the eighth day - rest, on the following three days the baths are being carried out for 15 minutes.

Method of complex therapy of fist time identified pulmonary tuberculosis

For complex therapy of the first time identified pulmonary tuberculosis traditional anti-tuberculosis therapy is carried out. After two weeks of anti-tuberculosis chemotherapy, complex physiotherapy is performed. In the morning 40-60 minutes after meal ultrasound inhalation with an inhibitor of proteases contrykal in a dose of 5000 UNITS, diluted in 3-4 ml of an isotonic solution of sodium chloride is carried out. Inhalation is carried out at a temperature of the solution of 35°C for 10 minutes on the apparatus "Vulkan-1". 20 minutes after inhalation magnetic infrared laser therapy (MIL-therapy) is performed from the apparatus "Rikta-04/4" on affected zones of the lungs by contact method of the application of the apparatus emitter. Frequency of the laser impact constitutes 5-50 Hz. Average power of infrared light-diode radiation is 60±30 mW, an impact with constant magnetic field is realised with induction 35±10 mT for 1-5 min. The course of treatment constitutes 30-40 daily procedures as well.

Methods of control and prevention of inflammation and relief of inflammatory conditions in companion animals

Invention relates to a method of prevention and to a method of control of inflammation and/or relief of inflammatory conditions in companion animals, including the introduction of a diet, which contains 50-250 ppm of lipoic acid, 500-2000 IU/kg of vitamin E, 40-200 ppm of vitamin C, 50-300 of carnitine and 1-10% counted per dry substance of vegetable mixture. The invention relates to the application of the said diet for obtaining a food product for pets for the prevention of inflammation and/or relief of inflammatory conditions.

5-amino-2-(1-hydroxyethyl)tetrahydropyran derivatives

Invention relates to antibacterial compounds of formula

Method of treatment and prevention of recurrences of intrauterine synechiae

For treatment and prevention of recurrences of the intrauterine synechiae within the range of pre-implantation preparation of the endometrium, heteroscopy with further installation of the child's Foley catheter into the uterine cavity is performed. The catheter balloon is filled with 2 ml of the physiological solution. The catheter is installed for 7 days, on which instillagel in a dose of 2.5 ml is introduced into the uterine cavity through holes in the distal end of the catheter on 1, 3, 5, 7 day alternating it with introduction of filgrastim in a dose of 100 mcg on 2, 4, 6 days. Instillation is realised at the background of performed hormonal therapy.

Method of drug dilation of rigid pupil before performing phacoemulsification

0.05 ml of a mixture of drug solutions, consisting of three parts: 0.02 ml of a 1% adrenalin solution, 0.02 ml of a 1% mesatonum solution and 0.01 ml of a 2% lidocaine solution is introduced by injection into the area of the limb on the boundary of non-transparent and transparent parts of the cornea. Injection is performed by means of an injection needle of 27 gauge (27G) in a dose of 1/3 of the mixture volume in three points: on 12 o'clock, 4 o'clock and 8 o'clock. The needle is punctured in to the depth S of the cornea thickness.

Peptide ligands of somatostatine receptors

Invention refers to peptide derivatives of general formula

Medication vincamin in form of matrix tablets for improvement of cerebral circulation and method of its manufacturing

Invention relates to field of medicine, namely to matrix tablets of vincamin, belonging to peripheral vasodilators and used as preparation improving cerebral circulation. Vincamin medication includes active substance vincamin and auxiliary substances magnesium stearate, lactose monohydrate, hypromelose, copovidone, silicon dioxide colloidal hydrophobic, silicon dioxide hydrophilic in amounts given in the invention formula.

Nutritive composition for mammal immune system improvement

Inventions group relates to food industry. The nutritive composition for improvement of the immune system with a mammal, preferably, with the human includes the following components: (a) at least 18 en% of protein material; (b) at least 12 wt % of leucine of the total quantity of protein material; (c) lipid fraction including at least one ω-3 polyunsaturated fatty acid chosen from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid; (d) immunomodulator.